Advaxis Reports First Quarter Ended January 31, 2021 Financial Results and Provides a Business Update

Continued enrollment in expanded ADXS-503 HOT program in NSCLC to explore potential to enhance and/or restore sensitivity to checkpoint inhibitors

ADXS-503 Phase 1/2 trial data presented at SITC demonstrated disease control rate of 67% and overall response rate of 17% in first six evaluable patients with immediate prior progression on KEYTRUDA®

$9.2M public offering strengthens balance sheet for continued execution

PRINCETON, N.J., March 16, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announces its financial results for the first quarter ended January 31, 2021 and provides a business update.

First Quarter Ended January 31, 2021 Financial Results and Recent Key Accomplishments:

  • Presented updated clinical data from the ongoing Phase 1/2 trial of ADXS-503 as a monotherapy and in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in non-small cell lung cancer (NSCLC) at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
    ° Disease control rate of 67% and overall response rate of 17% in first six evaluable patients with immediate prior progression on KEYTRUDA®. The first two patients treated in Part B combination arm that had achieved stable disease (SD) and partial response (PR) remain on treatment for 10 and 8 months, respectively
    ° Biomarker data across 9 patients across trial arms confirmed on-mechanism activation of innate and adaptive immune responses to ADXS-503 with transient elevation of immune-modulatory cytokines, activation of cytotoxic -and/or memory CD8+ T cells as well as 100% efficient priming by ADXS-503
    ° Across trial arms, ADXS-503 appeared safe and well tolerated as a monotherapy and in combination with KEYTRUDA® with no added toxicities from combination therapy
  • Announced upcoming presentation at the American Association for Cancer Research (AACR) 2021 Annual meeting, in collaboration with Precision for Medicine, on the development of a novel immunophenotyping assay to accurately evaluate PD-1 expression as a pharmacodynamic marker during PD-1 blockade treatment with pembrolizumab, and the correlation of changes in T cell populations with observed clinical activity in the ongoing ADXS-503 clinical trial
  • Announced receipt of funding milestone payment under ADXS-HER2 licensing agreement with OS Therapies
  • Announced closing of $9.2 million public offering of common stock and warrants, with proceeds being used to fund continued development and expansion of our product pipeline

Management Commentary

“We are encouraged by the growing body of evidence that suggest ADXS-503 has the potential to synergistically enhance and/or restore sensitivity to checkpoint inhibitors,” said Kenneth A. Berlin, President and Chief Executive Officer of Advaxis. “Based on our encouraging data, we are prioritizing the ongoing and recently expanded ADXS-503 trial in diverse treatment settings for NSCLC, and will remain focused on continued clinical execution. We look forward to our presentation at AACR, which will further expand upon the previously reported on-mechanism innate and adaptive immune stimulation which we believe are driving meaningful and durable clinical benefit for patients treated with ADXS-503. Our strengthened balance sheet leaves us well positioned to continue progress with our off-the-shelf neoantigen immunotherapy ADXS-HOT program, including our planned expansion into prostate cancer with ADXS-504, and we look forward to providing study updates in the coming months.”

First Quarter Ended January 31, 2021 Financial Results

Research and development expenses for the first quarter of fiscal year 2021 were $2.6 million, compared with $4.9 million for the first quarter of fiscal year 2020. The reduction of $2.3 million was primarily attributable to the substantial reduction in costs associated with the winding down of clinical studies that have been discontinued.

General and administrative expenses for the three months ended January 31, 2021 were approximately unchanged at $3 million, compared to $3 million in the same three-month period in 2020.

As of January 31, 2021, the Company had approximately $33.3 million in cash and cash equivalents. The Company believes this is sufficient capital to fund its obligations, as they become due, in the ordinary course of business until May 2022.

About Advaxis, Inc.
Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.

To learn more about Advaxis, visit and connect on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are any statements that express the current beliefs and expectations of management, including but not limited to statements related to the expected clinical development of the Company’s drug product candidates, statements about the Company’s balance sheet position, and statements related to the goals, plans and expectations for the Company’s ongoing clinical studies. These and other risks are discussed in the Company’s filings with the SEC, including, without limitation, its Annual Report on Form 10-K, filed on January 22, 2021, and its periodic reports on Form 10-Q and Form 8-K. Any statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements, which speak only as of the date they were made. The Company undertakes no obligation to update or revise forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA.

Tim McCarthy, LifeSci Advisors, LLC

(In thousands, except share and per share data)

January 31,

October 31,
Current Assets:        
Cash and cash equivalents $33,318  $25,178 
Deferred expenses  1,602   1,808 
Prepaid expenses and other current assets  608   865 
Total current assets  35,528   27,851 
Property and equipment (net of accumulated depreciation)  2,189   2,393 
Intangible assets (net of accumulated amortization)  3,404   3,261 
Operating right-of-use asset (net of accumulated amortization)  4,644   4,839 
Other assets  182   182 
Total assets $45,947  $38,526 
Current liabilities:        
Accounts payable $399  $410 
Accrued expenses  2,142   1,737 
Common stock warrant liability  44   17 
Current portion of operating lease liability  992   962 
Deferred revenue  -   165 
Total current liabilities  3,577   3,291 
Operating lease liability, net of current portion  4,795   5,055 
Total liabilities  8,372   8,346 
Commitments and contingencies – Note 9        
Stockholders’ equity:        
Preferred stock, $0.001 par value; 5,000,000 shares
authorized; Series B Preferred Stock; 0 shares issued and
outstanding at January 31, 2021 and October 31, 2020;
Liquidation preference of $0 at January 31, 2021 and
October 31, 2020
  -   - 
Common stock - $0.001 par value; 170,000,000 shares
authorized, 116,130,688 and 78,074,023 shares issued and
outstanding at January 31, 2021 and October 31, 2020,
  116   78 
Additional paid-in capital  452,174   440,840 
Accumulated deficit  (414,715)  (410,738)
Total stockholders’ equity  37,575   30,180 
Total liabilities and stockholders’ equity $45,947  $38,526 

The accompanying notes should be read in conjunction with the financial statements.


(In thousands, except share and per share data)

  Three Months Ended
January 31,
  2021  2020 
Revenue $1,615  $3 
Operating expenses:        
Research and development expenses  2,570   4,859 
General and administrative expenses  3,008   3,030 
Total operating expenses  5,578   7,889 
Loss from operations  (3,963)  (7,886)
Other income (expense):        
Interest income, net  1   66 
Net changes in fair value of derivative liabilities  (27  (37)
Other income  12   - 
Net loss before benefit for income taxes  (3,977)  (7,857)
Income tax expense  -   - 
Net loss $(3,977) $(7,857)
Net loss per common share, basic and diluted $(0.05) $(0.15)
Weighted average number of common shares outstanding,
basic and diluted
  83,943,982   51,747,246 

The accompanying notes should be read in conjunction with the financial statements.


(In thousands)

  Three Months Ended
January 31,
  2021  2020 
Net loss $(3,977) $(7,857)
Adjustments to reconcile net loss to net cash used in operating activities:        
Stock compensation  236   242 
Loss on change in value of warrants  27   37 
Loss on disposal of property and equipment  12   - 
Abandonment of intangible assets  -   232 
Depreciation expense  192   229 
Amortization expense of intangible assets  67   91 
Amortization of right-of-use asset  195   181 
Change in operating assets and liabilities:        
Prepaid expenses and other current assets  463   789 
Other assets  -   1 
Accounts payable and accrued expenses  394   (1,462)
Deferred revenue  (165  - 
Operating lease liabilities  (230)  (191)
Net cash used in operating activities  (2,786)  (7,708)
Cost of intangible assets  (210)  (238)
Net cash used in investing activities  (210)  (238)
Net proceeds of issuance of common stock  8,550   9,737 
Warrant exercise  2,586   - 
Proceeds from employee stock purchase plan  -   2 
Net cash provided by financing activities  11,136   9,739 
Net increase in cash and cash equivalents  8,140   1,793 
Cash and cash equivalents at beginning of period  25,178   32,363 
Cash and cash equivalents at end of period $33,318  $34,156 
Cash paid for taxes $-  $- 
Warrant liability reclassified into equity  -   2 
Amounts accrued for offering costs  -   109 

The accompanying notes should be read in conjunction with the financial statements.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.